Skip to content

Impact and cost effectiveness of a protocol for diagnosis and treatment of tuberculosis in HIV/AIDS patients

Impact on mortality and cost-effectiveness of a protocol for diagnosis and treatment of tuberculosis in People Living with HIV

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-22t943
Enrollment
Unknown
Registered
2015-07-16
Start date
2014-03-21
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis, latent tuberculosis, HIV/AIDS

Interventions

From the sample calculation and considering a loss of up to 30%, the intervention group will be composed of 1281 individuals. These individuals will be screened for tuberculosis (TB) from the first co
Procedure/surgery

Sponsors

Conselho Nacional d eDeswenvolvimento Cientifico e Tecnologico
Lead Sponsor
Fundacao de Amparo a Ciencia e Tecnologia do Estado de Pernambuco
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: HIV positive patients who were diagnosed with HIV; aged 18 years or over; and attended in Correia Picanco Hospital before initiating ART.

Exclusion criteria

Exclusion criteria: Being treated for TB; We have been treated for tuberculosis in the last three months; be receiving antiretroviral therapy over a month.

Design outcomes

Primary

MeasureTime frame
General mortality rate. intervention group: numbers of deaths from any cause in the intervention group * 100/ sample in the intervention group control group: numbers of deaths from any cause in the control group* 100/ sample in the control group We will measure the mortality rate one year after finishing the study.

Secondary

MeasureTime frame
Percentage of latent tuberculosis diagnosis (TBLI), tuberculosis (TB) confirmed and suspected TB, proportion of cure and death.For example: Percentage of TBLI in the control group: number of TBLI diagnosed in the control group * 100 / Sample in the control group We will measure the secondary outcomes one year after finishing the study

Countries

Brazil

Contacts

Public ContactNoemia Siqueira

Centro de Pesquisa Aggeu Magalhaes

consultpesca@ig.com.br+55 81 34447558

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 24, 2026